LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $837,184 | -42.9% | 709,478 | -31.8% | 0.00% | – |
Q2 2023 | $1,467,086 | -12.0% | 1,040,487 | -6.4% | 0.00% | – |
Q1 2023 | $1,668,000 | +130826.2% | 1,112,111 | +2.2% | 0.00% | – |
Q4 2022 | $1,274 | -99.9% | 1,088,579 | +3.8% | 0.00% | – |
Q3 2022 | $1,185,000 | -40.3% | 1,049,051 | -16.5% | 0.00% | – |
Q2 2022 | $1,986,000 | -30.3% | 1,256,932 | -32.0% | 0.00% | – |
Q1 2022 | $2,849,000 | -9.4% | 1,849,662 | +44.1% | 0.00% | – |
Q4 2021 | $3,145,000 | -43.7% | 1,283,277 | -42.1% | 0.00% | -100.0% |
Q3 2021 | $5,584,000 | +0.4% | 2,215,792 | +13.5% | 0.00% | 0.0% |
Q2 2021 | $5,564,000 | – | 1,952,108 | +2674020.5% | 0.00% | – |
Q1 2021 | $0 | -100.0% | 73 | -96.8% | 0.00% | – |
Q4 2020 | $4,000 | -66.7% | 2,262 | -82.0% | 0.00% | – |
Q3 2020 | $12,000 | +140.0% | 12,544 | +126.6% | 0.00% | – |
Q2 2020 | $5,000 | -96.6% | 5,536 | -96.9% | 0.00% | – |
Q1 2020 | $148,000 | +16.5% | 178,846 | +26.1% | 0.00% | – |
Q4 2019 | $127,000 | +262.9% | 141,846 | +300.1% | 0.00% | – |
Q3 2019 | $35,000 | – | 35,456 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |